Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Cardiology
•
Structural Heart Disease
How should one approach management of a patient with asymptomatic severe primary (prolapse) TR and normal RV function (EF and strain) but with RA/RV enlargement?
Related Questions
Would you recommend starting an SGLT-2 inhibitors in patients with non-severe aortic stenosis based on recent evidence suggesting it may slow progression of disease?
Are there instances where TAVR should be considered for patients with moderate AS and HFrEF?
Would it be reasonable to consider combined BAV plus staged PCI in a patient presenting with ACS and new LV systolic dysfunction, moderate aortic stenosis, and complex bifurcating left main disease and RCA CTO?
Are there any indications for valve intervention in asymptomatic patients with moderate AS?
Are there specific types of bioprosthetic valves that would make you inclined to choose VKA in lieu of a DOAC for systemic anticoagulation several months post-valve replacement?
In patients with contraindications to TEE and poor windows for TTE, what is the next best test to look for PFO?
Is there any role for routine CT TAVR a few months after TAVR to look for HALT?
Which anticoagulant (DOAC or Warfarin) would you recommend in the case of a 70-year-old male with persistent atrial fibrillation and history of rheumatic mitral stenosis now status post bioprosthetic MVR?
How would you approach anticoagulation management and consideration for PFO closure in patients with acute lower extremity DVTs involving the proximal deep veins and findings concerning for PFO on echocardiogram?
Are there any trans-cathter options available in a patient s/p m-TEER with residual severe MR with high surgical risk who has worsening heart failure symptoms?
